ClinicalTrials.gg
Status unknownNCT03404752Updated Jan 19, 2018

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

A Phase 3 interventional study of Peg-Filgrastim in Breast Cancer, sponsored by Gema Biotech S.A.. Status unknown at 1 site in Argentina. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-01-19.

Sponsored by Gema Biotech S.A. · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies testing pegfilgrastim in Breast Neoplasms — 2 open to participants now, 4 under way, 1 of them phase 3. pegfilgrastim · Breast Neoplasms.

Planned enrollment
16th of 30
120 · median 124
Started
2015
with 1 other
Phase 3
11 of 33
none open now
Registered
23rd of 33
by date
Lead sponsor
1 of 33
Gema Biotech S.A.

Among the 33 studies testing pegfilgrastim in Breast Neoplasms, this one is the 16th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2015, is one of 11 in phase 3, and was the 23rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 33 studies testing pegfilgrastim in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing pegfilgrastim in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, multicentre, Phase 3 study. Patients will be randomly assigned to the Study drug or its comparator. The study will be blinded for the staff members in charge of the endpoint assessment.

Read the detailed description

Eligible patients will be scheduled to receive a chemotherapy regimen with risk of febrile neutropenia ≥20%. Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMA BIOTECH, or Peg-Filgrastim of Roche).

A total of 4 or 6 cycles of chemotherapy supported by Peg-Filgrastim will be administered with an interval of three weeks between each cycle.

Patients will be followed up for 28± 3 days after the last dose of Peg-Filgrastim.

Hematological assessment (Absolute Neutrophil Count [ANC]) will be assessed on day 1 or up to -3 (before administration of anticancer chemotherapy), day 2 or 3 and 5 through 9 of the first cycle, and thereafter every day until post-nadir ANC recovery to ≥ 1.5 x 109/l following each cycle of chemotherapy. In the following cycles, hematological assessment shall be performed on day 1 or up to -3 (before administration of anticancer chemotherapy), on day 2 or 3 and on days 5 and 7. This schedule only applies if the subject did not develop Severe Neutropenia on the previous cycle. If the patient develops Severe Neutropenia on the first cycle or at any cycle, then the schedule corresponding to first cycle shall be followed.

During baseline (before the administration of Peg-Filgrastim), day 5 and day 9 following the first cycle of chemotherapy CD34+ (cluster of differentiation) count will be determined.

The study consists of:

  • Screening (up to 4 weeks)
  • Treatment period (6 cycles each of 3 weeks. i.e. a total of 18 weeks)
  • Follow up period for safety (4 weeks after Peg-Filgrastim last dose)
03

Conditions studied

  • Breast Cancer

Keywords

  • breast cancer
  • chemotherapy
  • Neutropenia
  • Peg-filgrastim
  • biosimilar
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 70 years old.
  • Patients diagnosed having high risk stage 2 or stage 3 or 4 of breast cancer (by histopathological or cytological diagnosis) and need , adjuvant chemotherapy, or with disease.
  • A priori has been decided to be treated with Peg-Filgrastim and subjects eligible for Peg-Filgrastim therapy according to indications and clinical use in the product monograph
  • Patients scheduled to receive 4 or 6 cycles of chemotherapy (Taxane combinations) with prophylactic Peg-Filgrastim at 3 weeks interval. Monoclonal Antibodies in addition to Taxane regimens are permitted.
  • Any acute adverse effects of prior therapy must have resolved to ≤ (Version 4.0) grade 1 (excluding alopecia) prior to Day 1 of Cycle 1
  • - ECOG Performance Status 0, 1 or 2 as determined on Day 1 or up to -3 of Cycle 1 prior to administration of chemotherapy
  • Patients must have adequate organ function including the following:

    1. Adequate bone marrow functions, as determined within 3 days prior to administration of chemotherapy on Day 1 of Cycle 1 and as indicated by ≥9,5 g/dl (transfusion permitted to be included in the trial ),WBC (white blood cell) ≥3,5 x 109/l, (ANC) ≥1.5 x 109/l, ≥95 x 109/l;
    2. Adequate renal and hepatic function, as determined within 3 days prior to administration of chemotherapy on Day 1 of Cycle 1 and defined as follows,

      1. Hepatic: ≤ 1.5 x the (ULN) (unless elevation is known to be due to Gilbert's disease), Subjects must also meet one of the following criteria:

        1. Alkaline phosphatase within normal reference range and both (aspartate aminotransferase) and ALT (alanine aminotransferase) >2.5 x ULN; or
        2. Alkaline phosphatase \<2.5 x ULN and both AST and ALT \<1.5 x ULN; or
        3. Alkaline phosphatase \<5 x ULN and both AST and ALT within normal reference range;
      2. Renal: Serum creatinine ≤ 1.5 mg/dl or ≤ 60 ml/min (calculated according to the Cockcroft and Gault formula)
  • Patients of must have a negative pregnancy test within 3 days prior to the first dose of chemotherapy and at day 1 or up to -3 days of each Cycle) and use at least one form of as approved by the investigator during the study.
  • >6 months

Exclusion criteria

Exclusion Criteria:

Safety of treatment dependent criteria:

  • Presence of any serious concomitant systemic disorders incompatible with the administration of filgrastim, Peg-Filgrastim or any systemic disease that can influence the patient's safety according to doctor's diagnosis.
  • History of to Peg-Filgrastim, filgrastim or E.coli derived proteins.
  • Serious local infection or active systemic infection within 10 days prior to enrollment or patients who have taken antibiotics within the previous 10 days
  • Pregnant or breast-feeding patients
  • Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease ( III or IV)
  • Known bleeding disorder
  • Patient known to have , , or who have a positive serology for HIV, Hepatitis B or Hepatitis C at screening
  • History or presence of sickle cell disease
  • Concurrent or prior radiotherapy within four weeks of randomization

Criteria dependent on compliance with study procedures, or the evaluation of the response:

  • Unwilling to use a reliable and acceptable method throughout the study period (fertile patients only)
  • Treatment with certain other agents to treat the malignant disease
  • Known drug addiction, including alcoholism
  • Treatment with any product within 30 days prior to study drug administration
  • Concurrent prophylactic antibiotics
  • Previous participation in this study.
  • Already involved in another trial.
  • History of bone marrow or stem cell transplantation.
  • Previous therapy should not have included G-CSF (granulocyte-colony stimulating factor)

Previous participation in this study: Subjects who are considered screening failures are allowed to be re-screened, except if have started chemotherapy. In case of re-screening the following assessments and evaluations do not have to be repeated: Demographics, Medical history, HIV, Hepatitis B and C serology.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Peg-Neutropine®

    Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).

    Drug: Peg-Filgrastim

  • Active comparator
    Neulastim®

    Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).

    Drug: Peg-Filgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Efficacy: Duration (in days) of severe neutropenia-DSN

    ANC (Absolute Neutrophil Count) \< 500/mm3 in the first cycle of chemotherapy.

    Time frame: Day 5 to day 9 of the first cycle

Secondary outcomes

  1. Clinical Efficacy: Incidence of severe neutropenia

    ANC (Absolute Neutrophil Count) \<500/mm3 or 0.5 x 109/l not associated with fever across the cycles

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  2. ANC nadir

    Determination of ANC decreasing (depth of ANC nadir) and time to the post nadir ANC recovery (ANC ≥ 1500 /mm3)

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  3. Incidence of neutropenia

    Incidence of Grade 3 neutropenia (ANC \<1000 - 500/mm3) . incidence of Febrile Neutropenia-FN \[defined as ANC \<1000/mm3 or 1.0 x 109/l and a single temperature of \>38.3° C (101° F) or a sustained temperature of ≥38° C (100.4° F)\] for more than one hour by cycle and across the cycles. incidence of ANC \<500/mm3 and body temperature of \>38.3°C.

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  4. Fever

    Incidence of fever (temperature of \>38.3° C - 101° F)

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  5. infections

    Incidence of infections

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  6. IV anti-infectives

    Incidence of need for IV anti-infectives

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  7. Post-chemotherapy hospitalization

    Incidence and duration of post-chemotherapy hospitalization

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  8. Hospitalization due to neutropenia

    Incidence and duration of hospitalization as a result of neutropenia

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  9. Mortality

    Mortality due to infection

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  10. Pharmacodynamics

    The mobilization of CD34+ cells

    Time frame: Day 5 and 9 of the first cycle

  11. Incidence of Adverse Drug Reactions (safety and tolerability) as assessed by CTCAE v4.0

    Frequency of patients who withdraw the study drug due to lack of tolerance Frequency of patients who withdraw the study drug treatment due to any reason Incidence of local tolerability at the injection site

    Time frame: Day 5 to Day 21 during 4 - 6 cycles

  12. Immunogenicity

    Neutralizing Antibody (NABs) Titer and Binding Antibodies (BABs) to Peg-Filgrastim (anti-rG-CSF \[Recombinant Granulocyte-Colony stimulating factors\] antibodies greater or equal to a determined concentration expressed in U/mL) will be measured using validated methods

    Time frame: Day 5 and Day 28 of the last cycle

07

Study locations

1 of 1 sites recruiting
  • COIBA
    Buenos Aires, Bs As, Argentina
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Jun 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2016
First posted
Jan 19, 2018
Start
Aug 2015
Primary completionEst.
Jun 2018
CompletionEst.
Dec 2018
Last update
Jan 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03404752
Lead sponsor
Gema Biotech S.A.
Collaborators
QUID Quality in Drugs and Devices Latin American Consulting SRL
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Aug 2015
Primary completion
Jun 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Jan 19, 2018

Study contacts

Ezequiel Klimovsky, MD
Contact
eklimovsky@quid-consulting.com
54 11 4952 1360
Luciana Frassia
Contact
lfrassia@quid-consulting.com
54 11 4952 1360
Ezequiel Klimovsky, MD
study chair · QUID quality in drugs and devices LATAM consulting SRL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion